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Abstract 
Aims To conduct a randomized trial in order to guide the optimum therapy of 
symptomatic atrioventricular nodal reentrant tachycardia (AVNRT). 
Methods Patients with at least one symptomatic episode of tachycardia per month, and an 
electrophysiologic diagnosis of AVNRT, were randomly assigned to catheter ablation or 
chronic antiarrhythmic drug (AAD) therapy with bisoprolol (5 mg od) and/or diltiazem 
(120-300 mg od). All patients were properly educated to treat subsequent tachycardia 
episodes with autonomic maneuvers or a “pill in the pocket” approach. The primary end-
point of the study was hospital admission for persistent  tachycardia cardioversion, during 
a follow-up period of 5 years. 
Results Sixty one patients were included in the study. In the ablation group, one patient 
was lost to follow-up, and 29 were free of arrhythmia or conduction disturbances at a 5-
year follow-up. In the AAD group, 3 patients were lost to follow-up. Of the remainder, 10 
patients (35.7%) continued with initial therapy, 11 patients (39.2%) remained on 
diltiazem alone, and 7 patients (25%) interrupted their therapy within the first 3 months 
following randomization, and subsequently developed an episode requiring cardioversion. 
During a follow-up of 5 years, 21 patients in the AAD group required hospital admission 
for cardioversion. Survival free from the study end-point was significantly higher in the 
ablation group compared to the AAD group (log-rank test, P<0.001).  
Conclusions Catheter ablation is the therapy of choice for symptomatic AVNRT. AAD 
therapy is ineffective and not well tolerated. 
 
 
 
 3 
Key Words: atrioventricular; nodal; ablation; tachycardia; antiarrhythmic drugs 
 
 
 4 
Condensed abstract 
Sixty-one patients with AVNRT, were randomly assigned to catheter ablation or chronic 
antiarrhythmic drug (AAD) therapy with bisoprolol (5 mg od) and/or diltiazem (120-300 
mg od). During a follow-up of 5 years, survival free from hospital admission for 
persistent tachycardia cardioversion was significantly higher in the ablation group 
compared to the AAD group (log-rank test, P<0.001).  
 
 
What’s new? 
- Catheter ablation is the treatment of choice for symptomatic patients with 
AVNRT, by substantially improving quality of life, and reducing costs. 
- However, its potential superiority over antiarrhythmic drug administration or even 
watchful follow-up, has not been tested in a randomised trial.  
- We present the first randomised, controlled study that proves the superiority of 
ablation to drug therapy in AVNRT.  
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Introduction 
Although atrioventricular nodal re-entrant tachycardia (AVNRT) is the most common 
regular arrhythmia encountered in clinical practice, no randomised data exist to guide 
evidence-based therapy. Chronic administration of antiarrhythmic drugs decreases the 
frequency and the duration of AVNRT, but has a variable success in abolishing 
tachycardia episodes, ranging from 13 to 82%, and up to 20% of patients may discontinue 
therapy.1-10 Furthermore, particular antiarrhythmic medication may result in rare, but life-
threatening proarrhythmic effects.7-10 There has been evidence that catheter ablation is the 
treatment of choice for symptomatic patients, by substantially improving quality of life,11-
13 and reducing costs.14,15 However, its potential superiority over antiarrhythmic drug 
administration or even watchful follow-up,16 has not been tested in a randomised trial.  
 We have, therefore, conducted a randomised, controlled trial, to compare catheter 
ablation therapy to chronic antiarrhythmic drug administration in patients with frequent 
(>1/month), symptomatic episodes of AVNRT. To the best of our knowledge this is the 
first randomised, controlled study of its kind to be published. 
Methods 
Patients 
Adult patients, aged 18 to 65 years, with at least one symptomatic episode of tachycardia 
per month, at least one occasion of admission for cardioversion, and an electrophysiologic 
diagnosis of AVNRT at Athens Euroclinic, were recruited. AVNRT was diagnosed by 
fulfillment of established criteria during detailed atrial and ventricular pacing maneuvers. 
Exclusion criteria were concomitant structural heart disease, any degree of 
atrioventricular or intraventricular block on the 12-lead ECG, contraindications to beta 
blockers, pregnancy, or other comorbidity. The study received approval by our 
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institutional review board, and all patients provided a written, informed consent that had 
been fully explained prior to the electrophysiology procedure. 
Randomization 
Patients with a 12-lead ECG during tachycardia resembling AVNRT were invited to 
participate. If they consented and the diagnosis was confirmed, they were subjected to the 
randomization procedure. Immediately following electrophysiology study, consenting 
patients were randomly assigned to slow pathway catheter ablation by the same 
experienced operator (DGK), or to antiarrhythmic drug therapy. Patients who had 
provided an informed consent were allocated to treatment groups according to a 
computer-generated randomization procedure. The allocations were kept in sealed, 
opaque envelopes and treatment allocation was released to the study coordinator. In case 
of arrhythmia, patients were instructed to perform autonomic maneuvers (standing 
Valsalva, carotid sinus massage, or the diving reflex), and if this was not successful, and 
the patient had either abandoned drug medication or had been allocated to ablation, to 
take a single oral dose of diltiazem 120 mg and propranolol 80 mg.4,17 If the tachycardia 
persisted for more than 60 min after maneuvers or the “pill in the pocket” approach, 
patients had to seek medical attention for cardioversion, and the end-point of the trial was 
reached. Cardioversion was accomplished with intravenous adenosine (bolus of 6 or 12 
mg) as the treatment of choice, but IV verapamil (0.075-1.5 mg/kg) or diltiazem (0.15-
0.45 mg/kg), were also allowed in the absence of hypotension, at the discretion of the 
attending physician. 
 
 
Antiarrhythmic drug therapy  
 7 
Antiarrhythmic therapy consisted of a low dose of oral bisoprolol (5 mg once daily) and 
slow-release diltiazem (120-300 mg once daily) was started in all patients. If this resulted 
in AV nodal conduction disturbances, hypotension, or other complications, the patient 
was given the option to abandon therapy or to remain on the lower dose of diltiazem 
alone.  
Catheter ablation 
Anatomical slow pathway ablation was performed according to standard techniques.29,30 
Initially a right-sided slow pathway ablation was attempted, with care to keep the ablating 
catheter below the ostium of the coronary sinus as visualized in the RAO projection; 
ablation was not performed at the mid or anterior septum. End-points for ablation 
termination were demonstration of energy-induced junctional rhythm conducted to the 
atria, and non-inducibility of tachycardia with isoprenaline challenge. If RF-induction of 
junctional rhythm or non-inducibility of tachycardia could not be accomplished from the 
right side of the septum, left-sided slow pathway ablation through a trans-septal puncture 
was undertaken, as described elsewhere.18 Following successful ablation, patients were 
discharged from hospital within 24 hours on aspirin for one month, and no antiarrhythmic 
drugs. 
Study end-points 
The primary end-point of the study was admission to the hospital for tachycardia 
cardioversion following failure of the autonomic maneuvers or the pill in the pocket 
approach, where appropriate. All patients were followed-up for up to 5 years, unless if a 
study end-point occurred. Follow-up visits were scheduled at a 6-monthly basis. For 
patients referred from elsewhere, the referring physician was contacted.   
Statistical analysis 
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Sample size was estimated assuming an efficacy rate of 60% for medical therapy and 95% 
for catheter ablation, according to previously published studies.1-10,13 The required sample 
size to achieve 80% power when a=0.05 was 27 patients for each group. Continuous 
variables are presented as mean ± SD, and categorical variables are summarized as 
absolute and relative (%) frequencies. Freedom from the study end-point was determined 
using Kaplan-Meier analysis, and differences in free from the end-point survival were 
evaluated using the log rank test. All reported P values are based on two-sided tests and P 
<.05 was considered significant for all statistical determinations. All statistical 
calculations were performed using IBM SPSS Statistics version 22.0 (IBM Corp., 
Armonk, New York, USA). Power analysis was performed using MedCalc for Windows, 
version 14.8 (MedCalc Software, Ostend, Belgium). 
Results 
Patients 
Out of 407 patients who were referred for electrophysiology testing, and were diagnosed 
with AVNRT at Athens Euroclinic during the period 2000-2009, 61 patients were 
recruited to the trial. The mean age of all patients was 39.6±7.5 years (range 24 to51), and 
45 patients (74%) were female (Table 1). 
Catheter ablation 
All patients were subjected to conventional, right-sided ablation as described. In one 
patient a left-sided approach was successfully accomplished. No AV block was 
encountered, and no patient experienced AVNRT recurrence during the next 5 years 
following ablation (Figure 1). One patient was lost to follow-up. 
Antiarrhythmic Drug Therapy 
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Three patients were lost to follow-up. Of the remainder, 10 patients (35.7%) continued 
with initial therapy until admission for cardioversion or completion of follow-up, 11 
patients (39.2%) remained on diltiazem alone, and 7 patients (25%) interrupted their 
therapy within the first 3 months following randomization. They refused further drug 
therapy and, following admission for AVNRT, proceeded to ablation. At completion of 
follow-up, these patients remained free of sustained arrhythmia requiring cardioversion. 
Five of them had experienced tachycardia episodes that were either short-lived (<30 min) 
or interrupted by Valsalva maneuvers. One patient, female 48 years old, was admitted 
with AVNRT and hypotension that required fluid resuscitation following a single dose of 
diltiazem and propranolol. Within the next 1.7±1.8 years, 21 patients in the AAD group 
required hospital admission for cardioversion (Figure 1). Seven patients of the AAD 
group, 5 on bisoprolol and diltiazem, and 2 on diltiazem alone, remained free of 
arrhythmia. Survival free from the primary end-point was significantly higher in the 
catheter ablation group, compared to the antiarrhythmic drug therapy group (log-rank test, 
P<0.001)(Figure 2). 
Discussion 
Our data indicate that catheter ablation is the treatment of choice for patients with 
symptomatic AVNRT. Drug therapy, at least as administered in our study, is ineffective, 
and several of these, otherwise healthy, patients refuse to continue it. 
 Chronic administration of antiarrhythmic drugs for AVNRT has been tried in 
several previous trials. Verapamil has been mainly studied,1,2 but diltiazem has similar 
effects on the AV node.3 Beta blockers and digoxin are also probably of value but data are 
limited.2 Long-term therapy with a combination of diltiazem and propranolol has been 
successfully tried.4 Flecainide and propafenone are effective,5 probably more than 
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verapamil,6 but they are potentially proarrhythmic, and cases of ventricular tachycardia 
during prophylactic therapy of SVT have been reported both by the Propafenone PSVT 
and the FAPIS groups.7,8 Sotalol,9 and dofetilide10 have been found effective but potential 
proarrhythmia due to QT prolongation makes these agents less attractive for long-term 
therapy. The long-term use of amiodarone in this setting is prohibited by its 
complications. We chose bisoprolol and diltiazem based on their safety and tolerability 
profile, but still 68% of our patients could not tolerate both of them. In accordance with 
previous studies, 25% of our patients refused to follow any long-term drug therapy after 
having experienced the initial months of treatment. 
 Catheter ablation for AVNRT has been reported to offer a success rate of 95% 
with no procedure-related mortality, is associated with a risk of 0.5-1% AV block, and 
has an approximately 4% recurrence rate.13,19 With growing experience, these results can 
certainly improve. At Athens Euroclinic as well as Beth Israel Deaconess Medical Center, 
recurrence rate is less than 1.5%, and AV block is entirely preventable. This can be 
accomplished by avoiding an anterior approach and targeting only the anatomical area of 
the slow pathway either from the left or right septal side, avoiding the coronary sinus 
ostium, and terminating the energy delivery with the onset of a junctional rhythm, 
especially when not conducted to the atria.20 One of our cases required a left-sided access 
that was accomplished following trans-septal access. Although a left-sided approach may 
also be performed via a retrograde, trans-aortic access, the trans-septal approach allows 
better exploration of the posterior septum.  
Study limitations 
The main limitation of our study is the small number of our patients. However, recruiting 
patients who were about to undergo an electrophysiology study and had the option of ad 
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hoc ablation was not an easy task, and this is also reflected in the long recruitment period. 
Other centers that had been invited to participate in order to increase our numbers had 
also expressed these reservations. Thus, recruited population does not necessarily 
represents the average patient with AVNRT.  Second, our results of catheter ablation are 
derived from an experienced operator with a special interest in this arrhythmia and large 
experience on trans-septal puncture, and may not be valid for smaller volume centers. 
Finally, the combination of two safe but bradycardic drugs may have been responsible for 
the relatively high drop-out rate in the AAD group.  
Conclusion  
Patients with frequent, symptomatic episodes of AVNRT should be offered the option of 
catheter ablation. Chronic antiarrhythmic therapy, at least when restricted to drugs of 
known safety, is ineffective and not tolerated by a substantial number of patients.  
 
Figure 1. Randomisation and follow-up results. 
 
Figure 2. Arrhythmia-free survival during follow-up. 
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Table 1. Patient characteristics and clinical outcome 
 
Catheter ablation 
n =30 
Medical therapy 
n=31 
P-value 
 
Age (years) 
41.3±6.9 38.1±7.9 0.098 
 
Female gender (%) 
23 (77%) 22 (71%) 0.772 
 
Tachycardia Cycle 
Length (ms) 
330.3±44.9 321.0±32.0 0.355 
 
Episodes per month 
2.3±1.4 2.1±1.1 0.636 
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